Q3 2024 saw 24% revenue growth and 31% higher EBITDA, with strong gains in medical equipment and radio-pharmaceuticals. The group is spinning off its R&D/new molecules business and expects continued growth in recurring revenues and regional expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.